Please login to the form below

Not currently logged in

FDA approves Seagen’s Adcetris combination for paediatric patients with Hodgkin lymphoma

Patients had a 59% reduction in the risk of disease progression or relapse, second cancer or death


The US Food and Drug Administration (FDA) has approved Seagen’s Adcetris (brentuximab vedotin) for the treatment of paediatric patients aged two years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC).

The FDA’s decision was based on positive results from the phase 3 AHOD1331 study in which patients receiving the combination treatment achieved superior event-free survival compared to patients who received standard of care chemotherapy alone.

AHOD1331 is, as the company reports, the largest multicentre, randomised, open-label phase 3 immunotherapy study ever conducted with newly diagnosed high risk Hodgkin lymphoma (HL) paediatric patients.

The study enrolled 587 patients aged from two to 21 years across 151 institutions who had previously untreated Hodgkin lymphoma (HL) classified as high risk.

Seagen reported that the study demonstrated a 59% reduction in the risk of disease progression or relapse, second cancer or death versus standard of care.

HL is a type of blood cancer that starts when lymphocytes, a type of white blood cell, grow out of control, causing swollen lymph nodes and growths throughout the body.

It represents about 6% of all childhood cancers and is the most common cancer diagnosed in adolescents ages 15 to 19 years, with about one-third of all HL patients classified as high risk.

Patients with cHL have abnormal white blood cells that usually have a special protein on their surfaces called CD30, a key marker of cHL.

Adcetris, which is being jointly developed by Seagen and Takeda, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalisation into CD30-expressing cells.

“We are excited about the approval of Adcentris for children and adolescents with high risk cHL because this medicine, which has become part of standard of care for adults with previously untreated advanced stage HL, will now be accessible to young patients as well,” said Sharon Castellino, professor, department of pediatrics, Emory University School of Medicine, AHOD1331 study chair and Children’s Oncology Group Hodgkin Lymphoma Disease Committee chair.

Article by
Emily Kimber

11th November 2022

From: Regulatory, Healthcare



Subscribe to our email news alerts


Add my company
Medscape Medical Affairs

Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...